Efficacy of Adjuvant Radioactive Iodine Therapy in Histological Variants of DTC: A Scoping Review.

IF 2.3 3区医学 Q1 OTORHINOLARYNGOLOGY

Head and Neck-Journal for the Sciences and Specialties of the Head and Neck Pub Date : 2025-03-31 DOI:10.1002/hed.28155

Brian A Keith, Evan S Chernov, Shaun A Nguyen, Jyotika K Fernandes, William G Albergotti

{"title":"Efficacy of Adjuvant Radioactive Iodine Therapy in Histological Variants of DTC: A Scoping Review.","authors":"Brian A Keith, Evan S Chernov, Shaun A Nguyen, Jyotika K Fernandes, William G Albergotti","doi":"10.1002/hed.28155","DOIUrl":null,"url":null,"abstract":"Background: The efficacy of adjuvant radioactive iodine (RAI) therapy in intermediate- and high-risk differentiated thyroid carcinoma (DTC) remains unclear, particularly for papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC).Methods: This scoping review, following PRISMA-ScR guidelines, analyzed studies from PubMed, Scopus, and CINAHL through July 14, 2023. Data on demographics, cancer characteristics, treatment details, and clinical outcomes were extracted. A limited meta-analysis of continuous measures, proportions, and hazard ratios was performed.Results: Nineteen studies were included, revealing significant variability across studies. Meta-analysis was limited to overall survival (OS) in intermediate-risk PTC due to methodological heterogeneity across studies. Kaplan-Meier survival curves were inconsistent, RAI activity was often unreported, and complications of RAI were rarely addressed.Conclusions: Methodological heterogeneity hinders the assessment of adjuvant RAI efficacy between histological variants. Further randomized trials with extended follow-up and improved reporting are needed to better compare the effects of adjuvant RAI in PTC and FTC.","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/hed.28155","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The efficacy of adjuvant radioactive iodine (RAI) therapy in intermediate- and high-risk differentiated thyroid carcinoma (DTC) remains unclear, particularly for papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC).

Methods: This scoping review, following PRISMA-ScR guidelines, analyzed studies from PubMed, Scopus, and CINAHL through July 14, 2023. Data on demographics, cancer characteristics, treatment details, and clinical outcomes were extracted. A limited meta-analysis of continuous measures, proportions, and hazard ratios was performed.

Results: Nineteen studies were included, revealing significant variability across studies. Meta-analysis was limited to overall survival (OS) in intermediate-risk PTC due to methodological heterogeneity across studies. Kaplan-Meier survival curves were inconsistent, RAI activity was often unreported, and complications of RAI were rarely addressed.

Conclusions: Methodological heterogeneity hinders the assessment of adjuvant RAI efficacy between histological variants. Further randomized trials with extended follow-up and improved reporting are needed to better compare the effects of adjuvant RAI in PTC and FTC.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Head and Neck-Journal for the Sciences and Specialties of the Head and Neck 医学-耳鼻喉科学

CiteScore

7.00

自引率

6.90%

发文量

278

审稿时长

1.6 months

期刊介绍： Head & Neck is an international multidisciplinary publication of original contributions concerning the diagnosis and management of diseases of the head and neck. This area involves the overlapping interests and expertise of several surgical and medical specialties, including general surgery, neurosurgery, otolaryngology, plastic surgery, oral surgery, dermatology, ophthalmology, pathology, radiotherapy, medical oncology, and the corresponding basic sciences.